Pre–CAR-T B-cell–directed immunotherapy exposure and outcomes after CD19 CAR-T for large B-cell lymphoma: An EBMT registry analysis

Résumé fourni par la source

CD19-directed chimeric antigen receptor T-cell therapy (CAR-T) is standard-of-care second-line treatment for relapsed or refractory large B-cell lymphoma (LBCL) [ 1 , 2 , 3 ]. Bispecific antibodies (BSA) and polatuzumab vedotin (pola) are increasingly used prior to CAR-T, but the impact of such exposure, particularly before leukapheresis, when therapies may affect T-cell collection and fitness, remains unclear [ 4 , 5 , 6 , 7 ]. We identified 1158 patients from 38 centers undergoing licensed CD19-directed CAR-T therapy (axicabtagene ciloleucel [axi-cel] or tisagenlecleucel [tisa-cel]) between January 2018 and July 2023 from the European Society for Blood and Marrow Transplantation (EBMT) registry (Table S1 , Fig. S1 ). Pre–CAR-T B-cell–directed immunotherapy (BCDI) was defined as exposure to bispecific antibodies, polatuzumab-based regimens, or other B-cell–directed agents excluding rituximab. Overall survival (OS) was the primary endpoint and outcomes were analyzed using multivariable Cox regression models adjusted for clinically relevant covariates.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.